세계의 페닐케톤뇨증(PKU) 시장 보고서(2025년)

Phenylketonuria (PKU) Global Market Report 2025

US $ 4,490 ￦ 6,219,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,990,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,761,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

페닐케톤뇨증(PKU) 시장 규모는 향후 몇 년 동안 높은 성장세를 보일 것으로 예상됩니다. 예측 기간의 성장은 유전자 치료의 채택 증가, 효소 대체 치료의 확대, 희귀 질환 연구에 대한 투자 증가, 개인 맞춤형 의약품에 대한 수요 증가, PKU 치료 보장에 대한 정부 지원 등에 기인한 것으로 볼 수 있습니다. 주요 트렌드에는 RNA 기반 치료법 개발, PKU 관리를 위한 디지털 헬스 솔루션의 부상, 생명공학 기업과 연구 기관 간의 협력 증가, 비식이 치료 대안에 대한 관심, PKU 환자를 위한 원격 의료 서비스 확대 등이 있습니다.

유전 질환의 발병률 증가는 향후 페닐케톤뇨증(PKU) 시장의 성장을 견인할 것으로 예상됩니다. 유전 질환은 유전자 또는 염색체의 돌연변이, 결실 또는 복제를 포함하여 개인의 DNA 이상으로 인해 발생하는 의학적 상태입니다. 이러한 질환의 유병률이 증가하는 이유는 산모의 연령 증가, 환경적 영향, 진단 기술의 발전, 인식 향상 등의 요인으로 인해 발견율이 높아졌기 때문일 수 있습니다. 페닐케톤뇨증은 유전성 효소 결핍이 어떻게 심각한 대사 합병증을 초래할 수 있는지 설명함으로써 유전 질환을 이해하는 데 중요한 역할을 합니다. 예를 들어, 2024년 3월, 영국에 등록된 자선단체인 Gene People은 유전 질환이 어린이 25명 중 1명에게 영향을 미치며 영국에서 240만 명 이상의 어린이와 성인에게 영향을 미친다고 보고했습니다. 또한 영국에서는 매년 약 3만 명의 신생아와 어린이가 유전 질환 진단을 받습니다. 결과적으로 유전 질환의 발병률이 증가함에 따라 페닐케톤뇨증(PKU) 시장이 확대되고 있습니다.

페닐케톤뇨증(PKU) 시장의 주요 기업들은 PKU 치료제의 효능과 안전성을 향상시키기 위해 기술 발전에 주력하고 있습니다. 이러한 혁신 중 하나는 인간의 생리적 조건을 모방하여 약물 흡수와 대사를 개선하는 생체 모방 기술을 사용하는 것입니다. 생체 모방 기술은 복잡한 인간 생물학을 시뮬레이션하고 인간의 약물 반응을 정확하게 예측하도록 설계된 일련의 하드웨어, 소모품 및 분석 프로토콜로 구성됩니다. 예를 들어, 2022년 10월 스위스에 본사를 둔 바이오 제약 회사인 릴리프 테라퓨틱스 홀딩 SA는 PKU 골라이크의 출시를 발표했습니다. 특허받은 의약품 수준의 생체 모방 기술을 사용하여 개발된 이 차세대 의료용 식품은 페닐케톤뇨증(PKU)의 식이 관리를 위해 설계되었습니다. PKU 골라이크는 과립, 패킷, 의료용 식품 바 형태로 제공되는 서방형 아미노산 제품입니다. 독특한 코팅으로 천연 단백질과 유사한 아미노산의 생리적 흡수를 가능하게 하는 동시에 불쾌한 맛, 냄새, 뒷맛을 감춰줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 페닐케톤뇨증(PKU) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 페닐케톤뇨증(PKU) 시장 : 성장률 분석
• 세계의 페닐케톤뇨증(PKU) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 페닐케톤뇨증(PKU) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 페닐케톤뇨증(PKU) 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 페닐케톤뇨증(PKU) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 고페닐알라닌혈증
• 경도 페닐케톤뇨증(PKU)
• 중등도 및 변이형
• 기존 페닐케톤뇨증(PKU)
• 세계의 페닐케톤뇨증(PKU) 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 효소 대체 치료
• 유전자 치료
• 약물 치료
• 식이 치료
• 세계의 페닐케톤뇨증(PKU) 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 유전자 검사
• 생화학 검사
• 신생아 스크리닝
• 세계의 페닐케톤뇨증(PKU) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 전문 클리닉
• 연구기관
• 재택 의료
• 병원
• 세계의 페닐케톤뇨증(PKU) 시장 : 고페닐알라닌혈증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경도 고페닐알라닌혈증
• 중등도 고페닐알라닌혈증
• 중증 고페닐알라닌혈증
• 세계의 페닐케톤뇨증(PKU) 시장 : 경도 페닐케톤뇨증(PKU) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 식이 관리에 의한 경도 PKU
• 효소 대체에 의한 경도 PKU
• 세계의 페닐케톤뇨증(PKU) 시장 : 중등도 및 변이형 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 약물 치료에 의한 중등도 PKU
• 치료 변형이 있는 변이형 PKU
• 세계의 페닐케톤뇨증(PKU) 시장 : 기존 페닐케톤뇨증(PKU) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 엄격한 식이 관리를 수반하는 전형적인 PKU
• 효소 대체 치료에 의한 기존 PKU

제7장 지역별 및 국가별 분석

• 세계의 페닐케톤뇨증(PKU) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 페닐케톤뇨증(PKU) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 페닐케톤뇨증(PKU) 시장 : 경쟁 구도
• 페닐케톤뇨증(PKU) 시장 : 기업 프로파일
  • Abbott Laboratories 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck KGaA 개요, 제품 및 서비스, 전략 및 재무 분석
  • Agios Pharmaceuticals Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • BioMarin Pharmaceutical Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • PTC Therapeutics Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Ultragenyx Pharmaceutical Inc.
• Nutricia International Private Limited
• Codexis Inc.
• Eton Pharmaceuticals Inc.
• Vitaflo International Ltd.
• American Gene Technologies International Inc.
• Cambrooke Therapeutics Inc.
• Generation Bio Co.
• Mead Johnson & Company, LLC
• Relief Therapeutics Holding SA
• SOM Innovation Biotech SA
• Synlogic Inc.
• Galen Ltd
• Aptatek Biosciences Inc.
• Homology Medicines Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 페닐케톤뇨증(PKU) 시장(2029년) : 새로운 기회를 제공하는 국가
• 페닐케톤뇨증(PKU) 시장(2029년) : 새로운 기회를 제공하는 부문
• 페닐케톤뇨증(PKU) 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Phenylketonuria (PKU) is a rare inherited metabolic disorder in which the body is unable to break down the amino acid phenylalanine (Phe), which is present in many protein-containing foods. This condition results from a deficiency or malfunction of the phenylalanine hydroxylase (PAH) enzyme, which is responsible for converting phenylalanine into tyrosine.

The primary types of phenylketonuria (PKU) include hyperphenylalaninemia (HPA), mild PKU, moderate and variant PKU, and classic PKU. Hyperphenylalaninemia (HPA) is a genetic metabolic disorder caused by a deficiency of phenylalanine hydroxylase, leading to elevated levels of phenylalanine in the blood. Treatment options for PKU consist of enzyme replacement therapy, gene therapy, medication, and dietary therapy. Diagnosis methods include genetic testing, biochemical testing, and newborn screening. The key end users of PKU treatments and diagnostics include specialty clinics, research institutes, home healthcare providers, and hospitals.

The phenylketonuria (PKU) market research report is one of a series of new reports from The Business Research Company that provides phenylketonuria (PKU) market statistics, including the phenylketonuria (PKU) industry global market size, regional shares, competitors with the phenylketonuria (PKU) market share, detailed phenylketonuria (PKU) market segments, market trends, and opportunities, and any further data you may need to thrive in the phenylketonuria (PKU) industry. This phenylketonuria (PKU) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The phenylketonuria (PKU) market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to the expansion of newborn screening programs, increasing awareness of metabolic disorders, advancements in PKU dietary management, the growing availability of medical foods, and regulatory approvals for PKU treatments.

The phenylketonuria (PKU) market size is expected to see strong growth in the next few years. It will grow to $1.30 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to the increasing adoption of gene therapy, the expansion of enzyme replacement therapies, rising investments in rare disease research, growing demand for personalized medicine, and government support for PKU treatment coverage. Major trends include the development of RNA-based therapies, the rise of digital health solutions for PKU management, increased collaborations between biotech firms and research institutions, a focus on non-dietary treatment alternatives, and the expansion of telehealth services for PKU patients.

The rising incidence of genetic disorders is expected to drive the growth of the phenylketonuria (PKU) market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, including mutations, deletions, or duplications of genes or chromosomes. The increasing prevalence of these disorders can be attributed to factors such as rising maternal age, environmental influences, advancements in diagnostic technologies, and greater awareness, leading to improved detection rates. Phenylketonuria plays a key role in understanding genetic disorders by illustrating how inherited enzyme deficiencies can result in severe metabolic complications. For example, in March 2024, Gene People, a UK-based registered charity, reported that genetic conditions affect approximately 1 in 25 children, impacting over 2.4 million children and adults in the UK. Additionally, around 30,000 newborns and children in the UK are diagnosed with a genetic condition each year. As a result, the increasing incidence of genetic disorders is fueling the expansion of the phenylketonuria (PKU) market.

Leading companies in the phenylketonuria (PKU) market are focusing on technological advancements to enhance the efficacy and safety of PKU treatments. One such innovation is the use of physiomimic technology, which replicates human physiological conditions to improve drug absorption and metabolism. Physiomimic technology comprises a set of hardware, consumables, and assay protocols designed to simulate complex human biology and precisely predict human drug responses. For instance, in October 2022, Relief Therapeutics Holding SA, a Switzerland-based biopharmaceutical company, announced the launch of PKU Golike. This next-generation medical food product, developed using patented pharmaceutical-grade physiomimic technology, is designed for the dietary management of phenylketonuria (PKU). PKU Golike is a prolonged-release amino acid product available in granules, packets, and medical food bars. Its unique coating enables the physiological absorption of amino acids similar to natural proteins while masking their unpleasant taste, odor, and aftertaste.

In August 2024, Otsuka Holdings Co. Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for approximately $1.1 billion. Through this acquisition, Otsuka Pharmaceutical gains access to JNT-517, an oral drug for treating the rare genetic disorder phenylketonuria (PKU), while also strengthening its pipeline of innovative therapies for autoimmune diseases. Jnana Therapeutics Inc. is a US-based biotechnology company specializing in the treatment of phenylketonuria (PKU).

Major players in the phenylketonuria (pku) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company, LLC, Relief Therapeutics Holding SA, SOM Innovation Biotech S.A., Synlogic Inc., Galen Ltd, Aptatek Biosciences Inc., Homology Medicines Inc.

North America was the largest region in the phenylketonuria (PKU) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in phenylketonuria (PKU) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phenylketonuria (PKU) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phenylketonuria (PKU) market consists of revenues earned by entities by provide services such as enzyme therapy, screening tests, PKU tests, and PKU formula. The market value includes the value of related goods sold by the service provider or included within the service offering. The phenylketonuria (PKU) market also includes sales of sapropterin (Kuvan), pegvaliase-pqpz (Palynziq) and dietary supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phenylketonuria (PKU) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on phenylketonuria (pku) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for phenylketonuria (pku) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phenylketonuria (pku) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hyperphenylalaninemia; Mild Phenylketonuria (PKU); Moderate And Variant; Classic Phenylketonuria (PKU)
• 2) By Treatment Type: Enzyme Replacement Therapy; Gene Therapy; Medication; Dietary Therapy
• 3) By Diagnosis: Genetic Testing; Biochemical Testing; Newborn Screening
• 4) By End-User: Specialty Clinics; Research Institutes; Home Healthcare; Hospitals
• Subsegments:
• 1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia; Moderate Hyperphenylalaninemia; Severe Hyperphenylalaninemia
• 2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management; Mild PKU with enzyme supplementation
• 3) By Moderate And Variant: Moderate PKU with medication; Variant PKU with treatment variations
• 4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management; Classic PKU with enzyme replacement therapy
• Companies Mentioned:Abbott Laboratories; Merck KGaA; Agios Pharmaceuticals Inc.; BioMarin Pharmaceutical Inc.; PTC Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Phenylketonuria (PKU) Market Characteristics

3. Phenylketonuria (PKU) Market Trends And Strategies

4. Phenylketonuria (PKU) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Phenylketonuria (PKU) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Phenylketonuria (PKU) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Phenylketonuria (PKU) Market Growth Rate Analysis
• 5.4. Global Phenylketonuria (PKU) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Phenylketonuria (PKU) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Phenylketonuria (PKU) Total Addressable Market (TAM)

6. Phenylketonuria (PKU) Market Segmentation

• 6.1. Global Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyperphenylalaninemia
• Mild Phenylketonuria (PKU)
• Moderate And Variant
• Classic Phenylketonuria (PKU)
• 6.2. Global Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Gene Therapy
• Medication
• Dietary Therapy
• 6.3. Global Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing
• Biochemical Testing
• Newborn Screening
• 6.4. Global Phenylketonuria (PKU) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specialty Clinics
• Research Institutes
• Home Healthcare
• Hospitals
• 6.5. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Hyperphenylalaninemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Hyperphenylalaninemia
• Moderate Hyperphenylalaninemia
• Severe Hyperphenylalaninemia
• 6.6. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Mild Phenylketonuria (PKU), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild PKU with dietary management
• Mild PKU with enzyme supplementation
• 6.7. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Moderate And Variant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Moderate PKU with medication
• Variant PKU with treatment variations
• 6.8. Global Phenylketonuria (PKU) Market, Sub-Segmentation Of Classic Phenylketonuria (PKU), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic PKU with strict dietary management
• Classic PKU with enzyme replacement therapy

7. Phenylketonuria (PKU) Market Regional And Country Analysis

• 7.1. Global Phenylketonuria (PKU) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Phenylketonuria (PKU) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Phenylketonuria (PKU) Market

• 8.1. Asia-Pacific Phenylketonuria (PKU) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Phenylketonuria (PKU) Market

• 9.1. China Phenylketonuria (PKU) Market Overview
• 9.2. China Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Phenylketonuria (PKU) Market

• 10.1. India Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Phenylketonuria (PKU) Market

• 11.1. Japan Phenylketonuria (PKU) Market Overview
• 11.2. Japan Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Phenylketonuria (PKU) Market

• 12.1. Australia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Phenylketonuria (PKU) Market

• 13.1. Indonesia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Phenylketonuria (PKU) Market

• 14.1. South Korea Phenylketonuria (PKU) Market Overview
• 14.2. South Korea Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Phenylketonuria (PKU) Market

• 15.1. Western Europe Phenylketonuria (PKU) Market Overview
• 15.2. Western Europe Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Phenylketonuria (PKU) Market

• 16.1. UK Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Phenylketonuria (PKU) Market

• 17.1. Germany Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Phenylketonuria (PKU) Market

• 18.1. France Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Phenylketonuria (PKU) Market

• 19.1. Italy Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Phenylketonuria (PKU) Market

• 20.1. Spain Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Phenylketonuria (PKU) Market

• 21.1. Eastern Europe Phenylketonuria (PKU) Market Overview
• 21.2. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Phenylketonuria (PKU) Market

• 22.1. Russia Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Phenylketonuria (PKU) Market

• 23.1. North America Phenylketonuria (PKU) Market Overview
• 23.2. North America Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Phenylketonuria (PKU) Market

• 24.1. USA Phenylketonuria (PKU) Market Overview
• 24.2. USA Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Phenylketonuria (PKU) Market

• 25.1. Canada Phenylketonuria (PKU) Market Overview
• 25.2. Canada Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Phenylketonuria (PKU) Market

• 26.1. South America Phenylketonuria (PKU) Market Overview
• 26.2. South America Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Phenylketonuria (PKU) Market

• 27.1. Brazil Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Phenylketonuria (PKU) Market

• 28.1. Middle East Phenylketonuria (PKU) Market Overview
• 28.2. Middle East Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Phenylketonuria (PKU) Market

• 29.1. Africa Phenylketonuria (PKU) Market Overview
• 29.2. Africa Phenylketonuria (PKU) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Phenylketonuria (PKU) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Phenylketonuria (PKU) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Phenylketonuria (PKU) Market Competitive Landscape And Company Profiles

• 30.1. Phenylketonuria (PKU) Market Competitive Landscape
• 30.2. Phenylketonuria (PKU) Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Agios Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Phenylketonuria (PKU) Market Other Major And Innovative Companies

• 31.1. Ultragenyx Pharmaceutical Inc.
• 31.2. Nutricia International Private Limited
• 31.3. Codexis Inc.
• 31.4. Eton Pharmaceuticals Inc.
• 31.5. Vitaflo International Ltd.
• 31.6. American Gene Technologies International Inc.
• 31.7. Cambrooke Therapeutics Inc.
• 31.8. Generation Bio Co.
• 31.9. Mead Johnson & Company, LLC
• 31.10. Relief Therapeutics Holding SA
• 31.11. SOM Innovation Biotech S.A.
• 31.12. Synlogic Inc.
• 31.13. Galen Ltd
• 31.14. Aptatek Biosciences Inc.
• 31.15. Homology Medicines Inc.

32. Global Phenylketonuria (PKU) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Phenylketonuria (PKU) Market

34. Recent Developments In The Phenylketonuria (PKU) Market

35. Phenylketonuria (PKU) Market High Potential Countries, Segments and Strategies

• 35.1 Phenylketonuria (PKU) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Phenylketonuria (PKU) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Phenylketonuria (PKU) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료